-
Bayern and Kane gambling with house money as Gladbach come to town
-
Turkey invests in foreign legion to deliver LA Olympics gold
-
Galthie's France blessed with unprecedented talent: Saint-Andre
-
Voice coach to the stars says Aussie actors nail tricky accents
-
Rahm rejection of DP World Tour deal 'a shame' - McIlroy
-
Israel keeps up Lebanon strikes as ground forces advance
-
China prioritises energy and diplomacy over Iran support
-
Canada PM Carney says can't rule out military participation in Iran war
-
Verstappen says new Red Bull car gave him 'goosebumps'
-
Swiss to vote on creating giant 'climate fund'
-
Google to open German centre for 'AI development'
-
Winter Paralympics to start with icy blast as Ukraine lead ceremony boycott
-
Sci-fi without AI: Oscar nominated 'Arco' director prefers human touch
-
Ex-guerrillas battle low support in Colombia election
-
'She's coming back': Djokovic predicts Serena return
-
Hamilton vows 'no holding back' in his 20th Formula One season
-
Two-thirds of Cuba, including Havana, hit by blackout
-
US sinks Iranian warship off Sri Lanka as war spreads
-
After oil, US moves to secure access to Venezuelan minerals
-
Arteta hits back at Brighton criticism after Arsenal boost title bid
-
Carrick says 'defeat hurts' after first loss as Man Utd boss
-
Ecuador expels Cuba envoy, rest of mission
-
Arsenal stretch lead at top of Premier League as Man City falter
-
Title race not over vows Guardiola after Man City held by Forest
-
Rosenior hails 'world class' Joao Pedro after hat-trick crushes Villa
-
Brazil ratifies EU-Mercosur trade deal
-
Real Sociedad edge rivals Athletic to reach Copa del Rey final
-
Chelsea boost top four push as Joao Pedro treble routs Villa
-
Leverkusen sink Hamburg to keep in touch with top four
-
Love match: WTA No. 1 Sabalenka announces engagement
-
Man City falter as Premier League leaders Arsenal go seven points clear
-
Man City title bid rocked by Forest draw
-
Defending champ Draper ready to ramp up return at Indian Wells
-
Arsenal extend lead in title race after Saka sinks Brighton
-
US, European stocks rise as oil prices steady; Asian indexes tumble
-
Trump rates Iran war as '15 out of 10'
-
Nepal votes in key post-uprising polls
-
US Fed warns 'economic uncertainty' weighing on consumers
-
Florida family sues Google after AI chatbot allegedly coached suicide
-
Alcaraz unbeaten run under threat from Sinner, Djokovic at Indian Wells
-
Iran's supreme leader gone, but opposition still at war with itself
-
Mideast war rekindles European fears over soaring gas prices
-
'Miracle to walk' says golfer after lift shaft fall
-
'Nothing is working': Gulf travel turmoil hits Berlin tourism fair
-
Harvey Weinstein rape retrial to start April 14: publicist
-
No choke but 'walloping', South Africa coach says of T20 flop
-
Bayer gets preliminary approval for weedkiller class settlement
-
Russia to free two Hungarian-Ukrainian POWs, Putin says
-
Michelangelo's works hidden in 'secret room', researcher says
-
Adidas shares slump on outlook, Mideast war casts shadow
Study shows how fast kilos return after ending weight-loss drugs
When people stop taking the new generation of weight-loss drugs they pile back on the kilos four times faster than they would after ending diet and exercise regimes, new research found Thursday.
But this was mostly because they lost so much weight in the first place, according to the British researchers who conducted the largest and most up-to-date review of the subject.
A new generation of appetite-suppressing, injectable drugs called GLP-1 agonists have become immensely popular in the last few years, transforming the treatment for obesity and diabetes in many countries.
They have been found to help people lose between 15-20 percent of their body weight.
"This all appears to be a good news story," said Susan Jebb, a public health nutrition scientist at Oxford university and co-author of a new BMJ study.
However, recent data has suggested that "around half of people discontinue these medications within a year," she told a press conference.
This might be because of common side effects such as nausea or the price -- these drugs can cost over $1,000 a month in the US.
So the researchers reviewed 37 studies looking at ceasing different weight-loss drugs, finding that participants regained around 0.4 kilograms a month.
Six of the clinical trials involved semaglutide -- the ingredient used in Novo Nordisk's brands Ozempic and Wegovy -- and tirzepatide used for Eli Lilly's Mounjaro and Zepbound.
While taking these two drugs, the trial participants lost an average of nearly 15 kilograms.
However after stopping the medication, they regained 10 kilograms within a year, which was the longest follow-up period available for these relatively new drugs.
The researchers projected that the participants would return to their original weight in 18 months.
Measurements of heart health, including blood pressure and cholesterol levels, also returned to their original levels after 1.4 years.
People who were instead put on programmes that included diet and exercise -- but not drugs -- lost significantly less weight. However it took an average of four years for them to regain their lost kilos.
This meant that people taking the drugs regained their weight four times faster.
- 'Starting point, not a cure' -
"Greater weight loss tends to result in faster weight regain," lead study author Sam West of Oxford University explained.
But separate analysis showed that weight gain was "consistently faster after medication, regardless of the amount of weight lost in the first place," he added.
This could be because people who have learned to eat more healthily and exercise more often continue to do so even as they regain weight.
Jebb emphasised that GLP-1 drugs "are a really valuable tool in obesity treatment -- but obesity is a chronic relapsing condition."
"One would expect that these treatments need to be continued for life, just in the same way as blood pressure medication," Jebb said.
If this was the case, it would impact how national health systems judge whether these drugs are cost-effective, the researchers emphasised.
"This new data makes it clear they are a starting point, not a cure," said Garron Dodd, a metabolic neuroscience researcher at the University of Melbourne not involved in the study.
"Sustainable treatment will likely require combination approaches, longer-term strategies, and therapies that reshape how the brain interprets energy balance, not just how much people eat," he said.
A.Kunz--VB